Israeli radiopharmaceutical firm Isotopia Molecular Imaging and Austria-based Seibersdorf Labor have signed a production agreement for lutetium-177 (Lu-177), which is used to manufacture radioisotopes for cancers including neoendocrine and prostate.
The two firms will collaborate on building a production facility that should be ready by the end of next year. At that facility, Seibersdorf Labor will produce the radiopharmaceutical for European distribution.
